Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | DGKA | P23743 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29220673 | 0.87 | MAPT (0.36) | CYP19A1MAPTADRA2AADRA1ACHRNB2 | |
| SCHEMBL5907666 | 0.85 | ALOX15 (0.36) | CYP19A1MAPTTSHRADRA2AADRA1A | |
| SCHEMBL195816 | 0.84 | CYP19A1 (0.40) | CYP19A1MAPTADRA2AADRA1ACHRNB2 | |
| SCHEMBL22205226 | 0.84 | CYP19A1 (0.40) | CYP19A1MAPTADRA2AADRA1ACHRNB2 | |
| SCHEMBL13147621 | 0.84 | CYP19A1 (0.40) | CYP19A1MAPTADRA2AADRA1ACHRNB2 | |
| SCHEMBL19899224 | 0.84 | CYP19A1 (0.40) | CYP19A1MAPTADRA2AADRA1ACHRNB2 | |
| SCHEMBL22205224 | 0.84 | CYP19A1 (0.40) | CYP19A1MAPTADRA2AADRA1ACHRNB2 | |
| SCHEMBL21974553 | 0.84 | CYP19A1 (0.40) | CYP19A1MAPTADRA2AADRA1ACHRNB2 | |
| SCHEMBL431832 | 0.84 | CYP19A1 (0.40) | CYP19A1MAPTADRA2AADRA1ACHRNB2 | |
| SCHEMBL16053327 | 0.84 | CYP19A1 (0.40) | CYP19A1MAPTADRA2AADRA1ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228422-A1 | PROCESS FOR PREPARING OXOBUTANOL ESTERS OF POLYMERIC CARBOXYLIC ACIDS | KETOLIPIX THERAPEUTICS GMBH (DE) | 2024-07-11 | — | — | US | disclosed |
| US-20240228422-A1 | PROCESS FOR PREPARING OXOBUTANOL ESTERS OF POLYMERIC CARBOXYLIC ACIDS | KETOLIPIX THERAPEUTICS GMBH (DE) | 2024-07-11 | — | — | US | disclosed |
| US-20230303478-A1 | PROCESS FOR PREPARING CARBOXYLIC ACID ESTERS OF HYDROXYBUTANOATES | KETOLIPIX THERAPEUTICS GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230257337-A1 | METHOD FOR PRODUCING POLYGYLCEROL ESTERS OF POLYCARBOXYLIC ACIDS ESTERIFIED WITH OXOBUTANOL | KETOLIPIX THERAPEUTICS GMBH (DE) | 2023-08-17 | — | — | US | disclosed |
| US-20230257337-A1 | METHOD FOR PRODUCING POLYGYLCEROL ESTERS OF POLYCARBOXYLIC ACIDS ESTERIFIED WITH OXOBUTANOL | KETOLIPIX THERAPEUTICS GMBH (DE) | 2023-08-17 | — | — | US | disclosed |
| WO-2022012767-A1 | METHOD FOR PRODUCING POLYGLYCEROL ESTERS OF POLYCARBOXYLIC ACIDS ESTERIFIED WITH OXOBUTANOL | IOI OLEO GMBH (DE) | 2022-01-20 | — | — | WO | disclosed |
| WO-2022012765-A1 | PROCESS FOR PREPARING CARBOXYLIC ACID ESTERS OF HYDROXYBUTANOATES | IOI OLEO GMBH (DE) | 2022-01-20 | — | — | WO | disclosed |
| WO-2022012766-A1 | PROCESS FOR PREPARING OXOBUTANOL ESTERS OF POLYMERIC CARBOXYLIC ACIDS | IOI OLEO GMBH (DE) | 2022-01-20 | — | — | WO | disclosed |
| US-5126373-A | Ester or diester of 1,3-butanediol or 1,3-pentanediol; side effect reduction | BRUNENGRABER HENRI (US) | 1992-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228422-A1 | PROCESS FOR PREPARING OXOBUTANOL ESTERS OF POLYMERIC CARBOXYLIC ACIDS | C9, HAO2, HSD17B12 | CYP19A1 1222/4885MAPT 4124/4885TSHR 4392/4885 |
| US-20230303478-A1 | PROCESS FOR PREPARING CARBOXYLIC ACID ESTERS OF HYDROXYBUTANOATES | HAO2, HSD17B12, HCAR3 | CYP19A1 854/4885MAPT 4418/4885TSHR 3810/4885 |
| US-20230257337-A1 | METHOD FOR PRODUCING POLYGYLCEROL ESTERS OF POLYCARBOXYLIC ACIDS ESTERIFIED WITH OXOBUTANOL | ACACB, HSD17B12, MCCC2 | CYP19A1 1559/4885MAPT 3704/4885TSHR 3845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.